On October 3, 2026, a new publication involving vosoritide appeared in the Journal of Clinical Medicine. The article is titled "Retinal Structural and Microvascular Findings During Novel NPR-B-Targeted Vosoritide Therapy in Children with Achondroplasia." Vosoritide is an approved therapy. This publication is listed under PubMed ID 42882122. The title indicates the study addresses retinal structural and microvascular observations in children with achondroplasia who are receiving vosoritide therapy, which targets the NPR-B pathway. No specific findings, outcomes, or conclusions from the study have been provided beyond the title and journal of publication. Readers interested in the details of the methodology or results should consult the full article directly. For general background on vosoritide, including its approved indications and regulatory status, readers can refer to the compound overview.
New Publication on Vosoritide and Retinal Findings in Achondroplasia
See the full vosoritide overview
Source: https://pubmed.ncbi.nlm.nih.gov/42882122/